KRISTEN MAXWELL: Open Payments
NPI 1396353355 · DEMOREST, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$654 in 33 payments from 19 companies in 2025. Trend: 2023 $908 · 2024 $735 · 2025 $654
Food & beverage: $654
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| ABBVIE INC. | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Exact Sciences Corporation | 2 | $39 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: GVOKE HYPOPEN, FANAPT, REXULTI, TRELEGY ELLIPTA, FARXIGA, Cologuard Collection Kit, JOURNAVX, UBRELVY.
Industry payments across GA — which companies pay providers there.
